DUBLIN--(BUSINESS WIRE)--The "Lyme disease (LD)- Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
According to this research, the market of Lyme disease (LD) in 7MM was found to be 403.64 million in 2016, and is expected to increase from 2016-2027.
The United States accounts for the largest market size of Lyme disease (LD) in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
According to this research, total incident population of Lyme disease (LD) in the 7 major markets is estimated approximately 489,605 cases in 2016 and it is expected to change in 2027.
This research estimates that the incident population of Lyme disease (LD) will significantly change during the study period [2016-2027].
The research estimates a higher diagnosed incidence of Lyme disease (LD) in the United States with 280,152 diagnosed cases in 2016.
Drug Chapters
Currently, the therapeutic options comprises the use of antibiotics for the treatment of Lyme disease (LD). The present market does not holds any approved drug for Lyme disease (LD). The situation is equally crucial for the emerging therapies. The thin pipeline activities in this space makes the situation even more complicated. In the current scenario, the pipeline holds only one active product, VLA15 being developed by Valneva.
Expected Launch of potential therapies (currently only one i.e., VLA15) may increase market size in the coming years, assisted by an increase in diagnosed incident population of Lyme disease (LD). Owing to the positive outcomes during the early stage trials along with the Fast track Designation the only upcoming therapy VLA15 by Valneva has a potential to create a significant positive shift in the Lyme disease (LD) Market Size.
2. Lyme Disease (LD) Market Overview at a Glance
3. Disease Background and Overview: Lyme Disease (LD)
4. Epidemiology and Patient Population
5. 7MM
6. Country Wise-Epidemiology of Lyme Disease (LD)
7. Treatment
8. United States Guideline on Lyme Disease (LD)
9. European Guideline on Lyme Disease (LD)
10. Unmet Needs
11. Emerging Drugs
12. Lyme Disease (LD): 7 Major Market Analysis
13. The United States Market Outlook
14. EU-5 Countries: Market Outlook
15. Japan: Market Outlook
16. Market Drivers
17. Market Barriers
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wr7hsf/global_lyme?w=4
